<DOC>
	<DOCNO>NCT01663441</DOCNO>
	<brief_summary>This phase Ⅲ trial divide two stage , Ⅲa Ⅲb.The aim Ⅲa evaluate optimal dose dose genetically modify recombinant human IL-11 ( mIL-11 ) multicenter randomize self-control trial involve 60 cancer patient undergo chemotherapy.The aim Ⅲb evaluate efficacy safety genetically modify recombinant human IL-11 ( mIL-11 ) , use rhIL-11 active control , multicenter randomize trial involve 240 cancer patient undergo chemotherapy .</brief_summary>
	<brief_title>A Phase Ⅲ Study Genetically Modified Recombinant Human Interleukin-11</brief_title>
	<detailed_description>The investigator recently develop mutant form rhIL-11 improved stability . In vitro experimental system , mIL-11 show endure chemical proteolytic stress effectively , retain biological activity original rhIL-11 . The improved stability mIL-11 also demonstrate comparative pharmacokinetic study subcutaneously deliver mIL-11 rhIL-11 rodent primate model . Based improved pharmacokinetic pharmacodynamic feature . In Phase II study show mIL-11 well tolerated thrombopoietic activity equivalent one third clinical dose rhIL-11 , indicate potential mIL-11 use treatment CIT . This study phase III , single-blinded , randomize , multicenter , cross-over study design evaluate optimal dose dose efficacy safety mIL-11 CIT patient receive suitable chemotherapeutic regimen treat cancer .</detailed_description>
	<mesh_term>Thrombocytopenia</mesh_term>
	<mesh_term>Oprelvekin</mesh_term>
	<criteria>histological verification malignancy time initial diagnosis； Patients ( age,1875 year ) receive chemotherapy , experience platelet count 75×10^9/L； patient require adequate bone marrow , hepatic , renal function time study entry； ECOG ≤2； patient normal laboratory finding : white blood count &gt; 3.0×10^9/L , platelet count ≥100×10^9/L , AST and/or ALT lesser 2.5 time upper limit normal value； The estimated life expectancy patient 3 month . ； patient receive total body irradiation； patient childbearing potential； patient breastfeed pregnant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Chemotherapy</keyword>
	<keyword>Thrombocytopenia</keyword>
	<keyword>Interleukin-11</keyword>
	<keyword>Platelet</keyword>
</DOC>